The Alzheimer's Association has reacted with disappointment to the topline results of the Phase 3 evoke and evoke+ studies: The oral diabetes medication semaglutide, in tablet form, was unable to statistically significantly slow or stop the course of early symptomatic Alzheimer's disease. Over 3,800 patients aged 55 to 85 with mild cognitive impairment or mild dementia (stages 3 and 4) participated in the two large international studies.
Although the drug improved Alzheimer's-related Biomarkers in both studies, this was not reflected in a delay of clinical progression. The Alzheimer's Association emphasizes that even negative study results are valuable: They contribute to understanding the disease and help to design future studies better.
The organization remains optimistic. There are currently 182 active clinical trials with 138 new active substances. Experts assume that an effective therapy in the future will consist of personalized combinations of several approaches. The Alzheimer's Association supports such innovative projects, among other things, through its 'Part the Cloud' program and calls on those affected to talk to their doctor about approved treatment options and participation in studies.
A detailed analysis of the data is expected in December at the Clinical Trials in Alzheimer's Disease (CTAD) conference.
